Senstend (lidocaine;prilocaine)
- Region
- 🇪🇺 EU
- Active substance
- lidocaine;prilocaine
- Company
- Plethora Pharma Solutions Limited
- Status
- Withdrawn
- Therapeutic area
- Premature Ejaculation
- CHMP opinion
- Thu 19 Sep 2019
- EU approval
- Thu 14 Nov 2019
- Application
- EMEA/H/C/005298
- ATC
- N01BB20
- Official record
- www.ema.europa.eu
Indication
Senstend is indicated for the treatment of primary premature ejaculation in adult men.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Fortacin Authorised · Recordati Ireland Ltd.
Follow Senstend
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.